Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Conditions
- Diffuse Large B-cell-lymphoma
- DLBCL, Nos Genetic Subtypes
- Follicular Lymphoma Grade 3B
- PMBL
- HGBL With MYC and BCL2 and/or BCL6 Rearrangements
- HGBL, Nos
Interventions
- BIOLOGICAL: C402-CD19-CAR
Sponsor
Shanghai Exuma Biotechnology Ltd.
Collaborators